It is well known that TGF‐β signaling activation plays a central role in IPF[1] and Exo treatments demonstrated broad downregulation of pro‐TGF‐β signaling (Figure 4A). The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.